Drugs / Bacille Calmette-Guérin (BCG)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04379336 | May 2020 → Jan 2022 | COVID-19 | TASK Applied Science | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT04537663 | Sep 2020 → Jul 2021 | COVID-19, respiratory tract infectious disorder | UMC Utrecht | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacille Calmette-Guérin (BCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537663 ↗ |
| Known as | BCG vaccine | “licensed BCG vaccine (Danish strain 1331, SSI, Denmark)” NCT04537663 ↗ |
| Modality | Vaccine | “BCG is a vaccine against tuberculosis (TB)” NCT04379336 ↗ |